Open-label, dose confirmation study of interstitial 131I-chTNT-1/b mab for the treatment of glioblastoma multiforme (GBM) at first relapse: Interim results.

W R Shapiro,J Shan,S J Patel,D Gupta,A K Mahapatra,S Gopal,K Judy

doi:10.1200/jco.2011.29.15_suppl.2035

Open-label, dose confirmation study of interstitial 131I-chTNT-1/b mab for the treatment of glioblastoma multiforme (GBM) at first relapse: Interim results.

W R Shapiro, J Shan + Show 5 more

https://doi.org/10.1200/jco.2011.29.15_suppl.2035

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2011
Citations: 2

#Glioblastoma Multiforme #Interim Results #Surgical Resection #Radiation Therapy #Aggressive Tumor #Primary Tumor #Dose Confirmation Study #Treatment Of Glioblastoma Multiforme #Recurrent Glioblastoma Multiforme #Primary Brain Tumor

Abstract
Full-Text
Similar Papers

Abstract

Listen

2035 Background: GBM is the most common and clinically aggressive primary brain tumor. For recurrent GBM, treatment by surgical resection, radiation therapy, and chemotherapy remains palliative, an...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Open-label, dose confirmation study of interstitial 131I-chTNT-1/b mab for the treatment of glioblastoma multiforme (GBM) at first relapse: Interim results.